Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1 [0.03%]
LAG-3Ig和抗PD-1/抗PD-L1抗体联合治疗癌症的专利分析：US2018271940A1
Martin Perez-Santos,Maricruz Anaya-Ruiz,Jorge Cebada et al.
Martin Perez-Santos et al.
LAG-3 is checkpoint inhibitor in cancer that coordinates the down regulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of LAG-3 and con...
Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018) [0.03%]
白介素-1受体相关激酶4(IRAK4)抑制剂的专利更新(2016-2018)
William T McElroy
William T McElroy
Introduction: Interleukin-1 receptor-associated kinase 4 (IRAK4) is the most upstream kinase in Toll/Interleukin-1 receptor (TIR) signaling. Human and rodent genetics support the role of IRAK4 in immune function and the i...
Marine natural products as source of new drugs: a patent review (2015-2018) [0.03%]
海洋天然产物作为新药来源的专利分析(2015-2018)
Pravin Shinde,Paromita Banerjee,Anita Mandhare
Pravin Shinde
Introduction: Natural products from plants, animals, microbes, and minerals have long been a traditional source for the treatment of human diseases. In the past decades, research on natural products for the pharmaceutical...
Simona Sestito,Simona Rapposelli
Simona Sestito
Introduction: 3-Phosphoinositide-dependent kinase 1 (PDK1), the 'master kinase of the AGC protein kinase family', plays a key role in cancer development and progression. Although it has been rather overlooked, in the last...
A patent update on cannabinoid receptor 1 antagonists (2015-2018) [0.03%]
cannabinoid受体1拮抗剂专利分析(2015-2018)
George Amato,Nayaab S Khan,Rangan Maitra
George Amato
Introduction: The endocannabinoid system is an important regulator of various physiological processes. Preclinical and clinical studies indicate that attenuation of the endocannabinoid system via antagonism of the type 1 ...
Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018) [0.03%]
布鲁顿酪氨酸激酶(BTK)抑制剂在癌症治疗中的应用：专利分析(2010-2018)
Yifan Feng,Weiming Duan,Xiaochuan Cu et al.
Yifan Feng et al.
Introduction: Bruton's tyrosine kinase (BTK) plays a critical role in the regulation of survival, proliferation, activation and differentiation of B-lineage cells. It participates by regulating multiple cellular signaling...
A spotlight on Brexit; what does the future hold for UK drug patent legislation? [0.03%]
聚焦英国脱欧：英国药品专利立法的未来会怎样？
Robert Watson
Robert Watson
A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018) [0.03%]
2014年至2018年MDM2/X靶向治疗的专利分析概要
Lukasz Skalniak,Ewa Surmiak,Tad A Holak
Lukasz Skalniak
Introduction: MDM2 and MDMX proteins provide the inhibition of p53 tumor suppressor, thus allowing for accelerated mutation-driven cancer microevolution. A pharmacological blockade of MDM2/X-p53 interaction results in p53...
A patent update on therapeutic applications of urease inhibitors (2012-2018) [0.03%]
脲酶抑制剂治疗应用专利研究报告(2012-2018)
Abdul Hameed,Mariya Al-Rashida,Maliha Uroos et al.
Abdul Hameed et al.
Introduction: Urease is a nickel-containing metalloenzyme that is commonly found in different bacteria, plants, algae, and fungi and mediates the growth of many pathogenic bacteria in the acidic environment of the stomach...
Luca Quattrini,Concettina La Motta
Luca Quattrini
Introduction: Aldose reductase (ALR2) is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of i...